Super Micro Computer Inc vs Sanofi SA — how do they compare? Super Micro Computer Inc trades at $38.48 (market cap $26.45B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 3.9× Super Micro Computer Inc's market cap, and Sanofi SA pays a 5.61% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| SMCI | SNY | |
|---|---|---|
Market Cap | $26.45B | $104.06B |
Sector | Technology | Health |
52-Week High | $58.68 | $52.34 |
52-Week Low | $20.53 | $41.33 |
Enterprise Value | $31.92B | $124.09B |
Dividend Yield | — | 5.61% |
Signals from Pluang's Aura AI — not financial advice
Super Micro Computer (SMCI) trades at $40.26, up 1.69% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals with a P/E of 12.35 and ROE of 26.53%, supported by AI-driven revenue growth and a record backlog. Recent news highlights strong AI infrastructure demand and insider selling of $7.7 million in shares.
Outlook remains positive given AI server demand and improving margins, but risks include cash flow volatility and competitive pressures. Analysts are mixed with a $40.57 consensus target, suggesting limited near-term upside from current levels amid execution and market sentiment risks.
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Trailing returns across standard periods
Latest headlines on both assets
Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →